Congressional Medicaid advisers are leaning toward recommending that Medicaid be allowed to restrict coverage of drugs while Medicare determines whether they are worth covering. The Medicaid and CHIP Payment and Access Commission (MACPAC) discussion on Thursday (Sept. 15) was spurred by coverage restrictions that Medicare placed on the Alzheimer’s drug Aduhelm, for which FDA granted accelerated approval based on a surrogate endpoint. Medicare adopted a policy, called a national coverage determination, that requires Biogen to further test the monoclonal antibody...